RIGL Rigel Pharmaceuticals, Inc.
Healthcare$29.17+0.55%ClosedMarket Cap: $539.7M
As of 2026-05-26
Valuation
P/E (TTM)
1.45
PEG
0.00
P/B
1.34
P/S
1.79
EV/EBITDA
4.25
DCF Value
$-37.28
FCF Yield
14.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.4%
Operating Margin
41.6%
Net Margin
121.5%
ROE
147.0%
ROA
72.2%
ROIC
28.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $58.8M | 92.2% | $11.9M | $8.7M | $— | — |
| Q4 null | $69.8M | 91.5% | $23.2M | $268.1M | $— | — |
| FY null | $294.3M | 93.3% | $125.5M | $367.0M | $— | — |
| Q3 null | $69.5M | 93.2% | $28.4M | $27.9M | $— | — |
| Q2 null | $101.7M | 95.6% | $61.1M | $59.6M | $— | — |
| Q1 null | $53.3M | 91.7% | $12.8M | $11.4M | $— | — |
| Q4 null | $57.6M | 89.9% | $16.7M | $14.3M | $— | — |
| FY null | $179.3M | 89.6% | $24.2M | $17.5M | $— | — |
| Q3 null | $55.3M | 85.5% | $14.1M | $12.4M | $— | — |
| Q2 null | $36.8M | 92.4% | $447.0K | $-1.0M | $— | — |
| Q1 null | $29.5M | 93.1% | $-7.0M | $-8.2M | $— | — |
| Q4 2023 | $35.8M | 89.4% | $2.0M | $737.0K | $0.04 | — |